FURTHER LOAN AGREEMENT

29th June 2007

Following the release of the preliminary results for the year to the 31st December, 2006 the company has entered into a further loan agreement with C.D.J. Pearce, the Chief Executive of the company under which he has agreed to increase the existing loan facility available to the company from £4m to £6m, in order to provide additional working capital for the group.

The facility is on identical terms to the agreement signed on the 29th June, 2006, full details of which are also disclosed in the company’s Report and Accounts for 2006 which are being posted to shareholders today.

As with the previous agreement, the loan facility therefore carries interest at 2.5% above the base rate of Barclays Bank plc and in view of the size of the loan facility, it has been agreed that security for the loan should be charged against the company’s patent portfolio up to the value of the loan outstanding and that the loan should be convertible into ordinary shares of the Company at the lower of market price on the date of conversion or the average price over the lowest consecutive ten day trading period since the 29th June, 2006 (the date on which details of the original loan agreement were disclosed).

The Directors of the Company, (with the exception of Mr. Pearce who in view of his interest in the transaction, has taken no part in consideration thereof) having consulted with its nominated adviser in relation to the loan facility from Mr. Pearce, consider that the terms of this transaction are fair and reasonable insofar as shareholders are concerned. The provision of this facility should allow the Company to complete the successful outlicencing of TMT® and to see it through to the revenue anticipated from its biomarker portfolio, ProteoSHOP® activities and from the warranty claim.